Bad debt? Or charity care? Sean Hamill of the Pittsburgh Post-Gazette recently wrote an interesting story about how hospitals increasingly are re-categorizing the health care bills of low-income patients in a fashion that may be helping the hospital more than the patient.
Some angles in this story are especially timely as the 2017 Affordable Care Act enrollment season is about to begin. Continue reading
Andy Slavitt, acting administrator for the Centers for Medicare and Medicaid Services, told D.C. health reporters he tries to be as direct and honest as possible when testifying in hyper-charged congressional hearings about the Affordable Care Act.
“I think of congressional oversight and my relationship with the media as very much an exercise in, ‘you guys see things I don’t,’” Slavitt said during an Oct. 6 panel discussion for AHCJ’s D.C. chapter, held at New York University’s D.C. campus. Continue reading
Medicaid enrollment has jumped 27 percent since the passage of the Affordable Care Act, with 31 states and the District of Columbia choosing to expand program eligibility. Medicaid now covers 72.8 million Americans.
But reimbursement rates for Medicaid remain lower than private insurance and a shortage of participating providers is causing access challenges. Continue reading
Local pharmacies have limited hours? Turns out that this is way more than an inconvenience. It may also be a factor in hospital readmissions. Patients who can’t easily get their medications from an accessible, nearby – and open! – pharmacy are more likely to end up back in the hospital.
Experts have been exploring possible reasons why so many patients bounce in and out of the hospital, and why it’s been hard to bring down the 30-day readmission rates, even with new financial incentives under the Affordable Care Act. Continue reading
Mylan’s price hike for its EpiPen allergy medication is just the latest example of health care costs pressuring consumers, Consumers Union’s Lynn Quincy told AHCJ members in a recent webcast.
Quincy, who leads the consumer-advocacy group’s Healthcare Value Hub and has backed efforts to curb rising drug prices, pointed to other recent price increases such as those by drugmakers Valeant and Turing as symptoms of a massive “market failure.” Continue reading